A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Study sponsor: Xencor, Inc. · XNCR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-10-15Estimated
Enrollment · participants170Estimated
Source updated2025-02-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.